This report presents a strategic analysis of the North America Neurology Drugs Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the North America Neurology Drugs Market, offering unmatched value, accuracy and expert insights.
North America's fastest-growing economy in 2021 was the United States. United States health spending is projected to have grown by 4.2% to $4.3 trillion in 2021, compared with a growth surge of 9.7% in 2020, according to the report from actuaries at the Centres for Medicare and Medicaid Services.
Total health spending in Canada reached a new level in 2021, at more than $308 billion, or $8,019 per Canadian. Health expenditure represented around 12.7% of Canada’s gross domestic product (GDP) in 2021, following a high of 13.7% in 2020. Governments and insurance stakeholders also need to discuss win-win reimbursement schemes that allow the democratization of telemedicine and provide lasting benefits for patients at an effective cost.
The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. Pharma revenues worldwide reached $1.42 trillion in 2021 due to the market's rapid growth over the previous two decades. With the introduction of new technology as well as more economical and effective manufacturing techniques, the pharmaceutical industry has experienced a significant transition. Additionally, the market growth has been positively driven by rising investment flow in this sector.
A neurological disease occurs when any portion of the brain or nervous system malfunctions, causing physical and/or psychological symptoms. Neurological disorders are treated with a variety of medications, including antipsychotics, antiepileptics, anticholinergics, and analgesics. Furthermore, the drug that is prescribed is primarily determined by the patient's neurological condition. These medications aid in the management of neurological conditions, symptom reduction, and improved quality of life.
The Global Neurology Drugs Market size is at around US $ 78.73 Bn in 2021 and is projected to reach US $ 125.31 Bn in 2030, exhibiting a CAGR of 5.3% during the forecast period.
Market Growth Drivers Analysis
An increase in the number of patients suffering from disorders, such as multiple sclerosis, Parkinson’s disease, cerebrovascular diseases, Alzheimer’s disease, and epilepsy is bolstering the market. The increase in the geriatric population, which is at higher risk of developing neurological disorders, is boosting the sales prospects in the North American market for neurological disorder drugs.
Key Players
Major players in Neurology Drugs Market are Merck KGaA (Germany), Eisai Co., Ltd. (Japan), AstraZeneca (U.K.), Sanofi (France), Novartis AG (Switzerland), Abbott (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Teva Pharmaceutical Industries Ltd. (Ireland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.)
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Disorder
This will provide beneficial opportunities for market growth. Brain injuries and neurological disorders are among the major causes of death around the world.
Drug Class
Distribution channel
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.